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Although inborn errors of metabolism do not represent the most common cause of
seizures, their early identification is of utmost importance, since many will require
therapeutic measures beyond that of common anti-epileptic drugs, either in order
to control seizures, or to decrease the risk of neurodegeneration. We translate the
currently-known literature on metabolic etiologies of epilepsy (268 inborn errors of
metabolism belonging to 21 categories, with 74 treatable errors), into a 2-tiered
diagnostic algorithm, with the first-tier comprising accessible, affordable, and less
invasive screening tests in urine and blood, with the potential to identify the majority
of treatable conditions, while the second-tier tests are ordered based on individual
clinical signs and symptoms. This resource aims to support the pediatrician, neurologist,
biochemical, and clinical geneticists in early identification of treatable inborn errors of
metabolism in a child with seizures, allowing for timely initiation of targeted therapy with
the potential to improve outcomes.
Keywords: inborn errors of metabolism, metabolic epilepsy, seizures, diagnostic algorithm, treatment
INTRODUCTION
The occurrence of epilepsy in the general population is relatively common. Just in the United States,
it affects 1.2% of the population, with 3 million adults and 470,000 children suffering from it (1). In
cases of neonatal seizures, inborn errors of metabolism (IEMs) account for 1.1% (2) −7.4% (3) of
all cases. Although IEMs are responsible for only a fraction of these cases, it is imperative to identify
them, as there is often treatment available which can mitigate or even prevent major neurological
sequelae (4). Elucidating the etiology of a seizure disorder can also prompt the investigation of
extra-neurologic systems commonly affected by IEMs (i.e., arrhythmias in mitochondrial disease,
liver disease, hearing or retinal involvement in peroxisomal disorders, etc.). It is important to
consider the possibility of an IEM in a patient presenting with seizures of an unknown cause not
only due to the amenability to causal treatment of the seizures and the possible co-morbidities,
but also in order to adequately perform genetic counseling and to more accurately predict the
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disease trajectory and prognosis. Finally, a timely diagnosis will
not only avoid unnecessary delay and burden to the patient,
it might also prevent failed attempts to control seizure with
standard antiepileptic drugs, often not without side effects, and it
has the potential to decrease the number and cost of unnecessary
tests.
Even when seizures are the major presenting feature of an
IEM, such as in pyridoxine-dependent epilepsy (PDE), diagnosis
is often difficult due to the broad differential diagnoses varying
from environmental to non-metabolic genetic etiologies (e.g.,
hypoxic-ischemic encephalopathy or genetic channelopathy) (5).
In addition, there is a great number of metabolic epilepsies,
posing a considerable challenge in identification based upon
primary symptomology; hence, standardized screening for a
subset for IEMs is advisable. Finally, the clinical picture even for a
specific metabolic condition may be often complex and mask an
otherwise evident IEM. An example is PDE, which can present in
the neonatal period not only with an epileptic encephalopathy
but also with metabolic acidosis, electrolyte disturbances,
abdominal distension mimicking sepsis, or structural brain
anomalies that might be considered a sufficient explanation for
seizures (5).
Patients with early-onset epilepsy can be evaluated in several
different departments within a given hospital, which necessitates
a standardized testing protocol in order to facilitate effective
coordination of the various departments, as well as to avoid
unnecessary diagnostic delay. Standardized testing will prevent
the administration of repeat tests, increasing the efficacy of
laboratory resources as well as diminishing cost. Finally, the
use of a standardized approach will avoid missed diagnoses,
especially for clinicians with less experience.
An indirect benefit from establishing an early diagnosis stems
from the fact that increased awareness of these IEMs can further
expand the knowledge base and clinical phenotype. For example,
pyridox(am)ine 5′-phosphate oxidase (PNPO) deficiency has, in
the past, been reported to have high mortality in the few cases
in which it was reported. However, awareness and subsequent
prompt diagnosis has increased survivability as well as expanded
the phenotype (6).
METHODS
Given themultitude of aforementioned benefits from establishing
an early diagnosis of IEMs, we propose a diagnostic approach
in patients with epilepsy, with emphasis on early identification
of those amenable to treatment. The algorithm is structured
according to the TIDE protocol for diagnosis of treatable
intellectual disabilities (7, 8). All metabolic conditions included
in the IEMbase tool [www.IEMbase.org; (9)] and in the
proposed Nosology (10) were individually searched along with
the terms “seizures,” “epilepsy,” or “convulsions” in Pubmed
(1966-December 2017) to identify all IEMs for which epilepsy
is a feature, and for which therapy targeting the underlying
pathophysiology is available and deemed at least partially
effective or preventive, with sufficient evidence (level IV or higher
according to the Center for Evidence-Based Medicine (CEBM).
RESULTS
Our systematic review identified 268 IEMs with epilepsy as a
primary or secondary feature, listed in Supplementary Table 1
following the nomenclature of IEMs of the recently-proposed
Nosology (10). Of these, 74 conditions are treatable. These
IEMs include disorders of amino acids (n = 43, 12 treatable);
sterols and bile acids (n = 7, 1 of which is treatable); creatine
(n = 3, all treatable); fatty aldehydes (n = 1, not treatable);
fatty acids, carnitine and ketones (n = 9, 6 treatable); complex
lipids (n = 8, none treatable); carbohydrates and polyols (n =
8, half of them treatable); lysosomes (n = 23, none treatable);
lipofuscin storage (n= 9, 1 treatable); metals (n= 5, 3 treatable);
mitochondria (n = 26, 7 treatable); autophagy (n = 2, neither
of which is treatable); neurotransmitters (n = 4, all treatable);
organic acids (n = 10, 6 treatable); peroxisomes (n = 7, 1
treatable); purines and pyrimidines (n = 5, 2 treatable); urea
cycle (n = 9, all treatable); vitamins/co-factors (n = 23, 12
treatable); glutathione (n = 1, not treatable), heme (n = 2, 1
treatable); and glycans and glycolipids (n = 63, 1 treatable).
The therapeutic modalities available for these IEMs include:
“sick–day” management, medical diets, cofactor/vitamin
supplements; substrate inhibition, stem cell transplant,
and gene therapy. Therapeutic effects vary from complete
control, improvement or prevention of epilepsy both clinically
and on EEG. Secondary outcomes include improvement
and/or stabilization of psychomotor/cognitive development;
behavior/psychiatric disturbances; seizures; and neurologic and
systemic manifestations (11). Supplementary Table 1 provides
more information on these IEMs, among others whether or not
included in newborn screening panels.
When to Suspect Metabolic Epilepsies
The presence of any of the following features should raise
suspicion for a metabolic etiology of epilepsy (12):
• Dysmorphic features (e.g., peroxisomal disorders, CDGs,
crotonase deficiency)
• Organomegaly
• Positive family history for similar condition or death of
unknown etiology
• Parental consanguinity
• Developmental regression after a period of apparent normalcy
• Fluctuating course of illness
• Ophthalmological problems (cataracts, retinitis pigmentosa,
cherry red spot, optic nerve atrophy)
• High-anion gap metabolic acidosis
• Neonatal ketonuria
• Unusual body fluid odor
• Seizures worsening with fasting (GLUT1) or with high protein
meals (urea cycle defects)
• Seizure worsening with anti-epileptic drugs
• Progressive myoclonic epilepsy phenotype in adolescence or
young adulthood.
The age of presentation can be a diagnostic indication of the
form IEM affecting the patient. Therefore, it is practical to
organize epilepsies caused by IEM according to age, which results
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TABLE 1 | Metabolic epilepsies classified according to age of onset.
NEONATAL-INFANTILE ONSET
Urea cycle disorders*
Maple syrup urine disease*
Organic acidemias*
Hepatocardiomuscular carnitine palmitoyltransferase II deficiency
Cobalamin C disease*
MTHFR deficiency*
Pyridoxine-dependent epilepsy*
Pyridox(am)ine 5’-phosphate oxidase deficiency*
PROSC deficiency*
Folinic acid responsive epilepsy*
GLUT1 deficiency*
Biotinidase deficiency*
Holocarboxylase synthetase deficiency*
Severe classic nonketotic hyperglycinemia
Serine biosynthesis defects*
Glutamine synthetase deficiency
Asparagine synthetase deficiency
Molybdenum cofactor deficiency
Isolated sulfite oxidase deficiency
Fumarate hydratase deficiency
Adenylosuccinate lyase deficiency type 1
GABA transaminase deficiency
Menkes disease*
Pyruvate dehydrogenase deficiency
Pyruvate carboxylase deficiency type A
Mitochondrial respiratory chain defects
Mitochondrial thiamine pyrophosphate transporter deficiency
Congenital disorders of glycosylation
Peroxisomal biogenesis disorders and D-bifunctional protein deficiency
Sialidosis type 2
Gaucher disease type 2
Prosaposin deficiency
Classic infantile GM1 gangliosidosis
Glycolipid synthesis deficiency (GM3 synthase and ST3GAL3 deficiencies)
Hyperinsulinism-hyperammonemia syndrome*
Disorders of lipoic acid synthesis
Mitochondrial glutamate transporter deficiency
Dihydrofolate reductase deficiency*
Glycosylphosphatidylinositol biosynthesis defects
Hypophosphatasia*
LATE INFANTILE
Creatine synthesis defects*
Organic acidemias*
Juvenile GM1 gangliosidosis
GM2 gangliosidosis
Classic late infantile neuronal ceroid lipofuscinosis*
Succinic semialdehyde dehydrogenase deficiency
CAD trifunctional protein deficiency*
GLUT1 deficiency*
Disorders of monoamine metabolism (AADC deficiency)*
Disorders of tetrahydrobiopterin metabolism (PTPS and DHPR deficiencies)*
(Continued)
TABLE 1 | Continued
Mitochondrial respiratory chain defects
Metachromatic leukodystrophy
Biotin-thiamine-responsive basal ganglia disease*
Congenital disorders of glycosylation
Folate receptor deficiency*
Dihydrofolate reductase deficiency*
Vici syndrome
Milder variants of PDE or PNPO deficiency*
Attenuated classic nonketotic hyperglycinemia*
LATE CHILDHOOD-ADOLESCENCE
Sialidosis type 1
Juvenile neuronal ceroid lipofuscinosis
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
(MELAS)
Myoclonic epilepsy with ragged-red fibers (MERRF)
Gaucher disease type 3
Niemann-Pick type C
X-linked adrenoleukodystrophy*
Primary CoQ deficiency*
Wilson disease*
Porphyria*
Aspartylglucosaminuria
Salla disease
Asterisks indicate treatable conditions.
in a distribution of epilepsies occurring in the neonatal or
infantile period, in early childhood, or those that present in late
childhood and adolescence. Table 1 outlines this organization.
This information may be useful in ordering Tier 2 testing.
The particular type of seizure can occasionally raise suspicion
for a specific disorder. For example, epilepsia partialis continua
can be the first clue toward a diagnosis of a POLG-
related disorder (13), patients with certain forms of congenital
disorders of glycosylation can present with migrating partial
seizures of infancy (14), while patients with guanidinoacetate
methyltransferase deficiency can have drop attacks and Lennox-
Gastaut syndrome (15). For other conditions, the evolution
of seizure over time have been well defined, such as for
Menkes disease, in which pattern of seizures can be divided
in three stages: an early stage at around 3 months showing
focal clonic status epilepticus, an intermediate stage at about 10
months showing intractable infantile spasms, and a late stage at
about 25 months showing multifocal seizures, tonic spasms and
myoclonus (16). In the majority of metabolic epilepsies, however,
the particular etiology of seizures cannot be predicted from its
semiology. A perfect example of this is that of GLUT1 deficiency,
in which the type of seizures is quite variable, beingmixed in 68%,
generalized tonic-clonic in 53%, absence in 49%, complex partial
in 37%, myoclonic in 27%, drop attacks in 26%, tonic in 12%,
simple partial in 3%, and spasms in 3% (17).
Although many IEMs will manifest with epilepsy refractory
to multiple standard anti-epileptic drugs (AEDs), a favorable
response to these drugs does not rule out metabolic epilepsies.
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For example, patients with GLUT1 deficiency can show response
to standard AEDs (17, 18), and patients with PDE can also show
some response (5), or can even show lack of seizures after a
period of time without pyridoxine supplementation (19). On
the other hand, the lack of response to standard treatment for
these conditions can also not be used as a criteria to rule out
the diagnosis: patients with GLUT1 deficiency can still show
recurrence of seizures despite adequate ketosis (20), and in fact
up to one third of patients respond poorly to a ketogenic diet (21),
while patients with PDE might not show an instant and obvious
response to pyridoxine administration (5).
Finally, the presence of specific electroencephalographic
(EEG) or brain neuroimaging findings can also provide
important clues toward the right diagnosis. Some IEMs can have
characteristic EEG changes, such as the comb-like rhythm seen
in patients with maple syrup urine disease (22). Certain IEMs
can be accompanied by structural brain anomalies identifiable by
brain MRI, such as a dysgenetic corpus callosum seen commonly
in patients with pyruvate dehydrogenase complex deficiency
or glycine encephalopathy (23). Brain magnetic resonance
spectroscopy can sometimes point toward the right diagnosis, as
has been reported in patients with GABA transaminase deficiency
(24), fatty acid oxidation disorders (25), mitochondrial disease
or glycine encephalopathy (26). Table 2 provides a summary of
the salient clinical, laboratory, electrographic, and neuroimaging
finding of the most common metabolic epilepsies.
Metabolic Investigational Algorithm for
Patients With Idiopathic or Early Onset
Epilepsy
Tier 1: Initial Screening in All Patients
We propose that the following initial screening investigations be
carried out for patients in whom epilepsy remains a prominent
feature of unknown cause. The tests included in the 1st tier:
(a) have the potential to identify 2 or more treatable metabolic
epilepsies; (b) are accessible via standard clinical chemistry and
biochemical genetics laboratories; (c) are relatively affordable and
covered by insurance; and (d) are non-invasive, requiring only
blood or dried blood spots and urine collection. Refer to Table 3
for test included in the first tier, and the abnormalities that can be
found in those tests in different IEMs.
Diagnostic therapies
Additionally, diagnostic therapy should be simultaneously
applied in infants, which will supplement testing in the
determination of etiology, and avoid therapeutic delay. For PDE,
100mg of pyridoxine should be given intravenously (on day 1–
3); samples can be collected after initiation of treatment. It is
important to emphasize that this should be administered in a
controlled setting (with resuscitation equipment available), since
up to 20% of patients will develop cerebral depression, with the
consequent risk of apnea. If responsive, then therapy should be
continued with pyridoxine 15–30 mg/kg/day orally or enteral
until diagnostic confirmation (elevated AASA in urine, blood
and/or CSF and absence of urine sulfocysteine and at least 1
disease-causing mutation in the ALDH7A1 gene). If seizures
are unresponsive to pyridoxine during 3 or more days, then
consider switching to pyridoxal 5′-phosphate (30 mg/kg/day
orally divided in 4 doses) to treat PNPO deficiency. Patients who
can swallow pills should do so, because aqueous PLP is subject to
photodegradation, and these degradation products can activate
hepatic stellate cells andmight lead to hepatic complications (27).
For younger children, the crushed tablet or content of the capsule
should be dissolved immediately before administration, and the
solution should be protected from light, to decrease the chance
of photodegradation. Not all brands of PLP have the advertised
amount of drug, with some brands have less or more content than
advertised; in the UK PLP tablets from Solgarr were found to be
the most reliable (28).
Alternatively, start with pyridoxine 15–30mg/kg/day orally or
enterally until results become available (if intravenous pyridoxine
administration is not possible); clinical improvement of seizures
is seen within minutes of intravenous pyridoxine administration,
while EEG improvement can be delayed (seen within hours),
and clinical improvement with oral pyridoxine can take 3–7
days to manifest. For biotinidase and holocarboxylase synthetase
deficiencies, start infants on biotin 10mg daily (until diagnosis is
ruled out).
Folinic acid-responsive seizures have been shown to be of
similar genetic origin to PDE (29); based upon this finding, we
have decided not to include folinic acid in the initial diagnostic
therapy step. Additionally, administration of folinic acid prior to
extraction of a CSF sample may confound diagnostic accuracy by
masking deficiency of methyltetrahydrofolate.
Tier 2: Additional Testing Under the Right Clinical
Circumstances
Additional tests may be ordered by the clinician according to
symptomatology and index of suspicion. This can be done in
parallel to the 1st tier mentioned above, or sequentially. The list
of these tests can be found inTable 4, along with the main clinical
findings that might elicit suspicion of one of the treatable or
non-treatable IEMs diagnosed with these tests.
Given the large number of treatable IEMs presenting with
epilepsy in infancy, and given that there are no clear clinical
indicators that would set them apart from other epilepsy
syndromes, we recommend that all infants presenting with
epilepsy should undergo a lumbar puncture and CSF biochemical
testing. In fact, the younger the infant, the more likely a lumbar
puncture will be performed in order to rule out meningitis or
viral encephalitis. It should be noted that the blood sample for
glucose should always be obtained before the CSF sample is
obtained, as otherwise the catecholaminergic response to the
lumbar puncture would increase the serum glucose and alter
the ratio. Similarly, the lumbar puncture should be collected
while the patient is off intravenous dextrose, and fasting. Specific
cutoffs for establishing the diagnosis of GLUT1 deficiency based
on CSF glucose, CSF lactate, and CSF-to-blood glucose ratio have
been published (30). Since the blood sample would be obtained
before the lumbar puncture, a sample for plasma amino acids
should be collected at the same time. For sampling of CSF
neurotransmitters, it is important to note that a rostrocaudal
gradient exists for metabolites derived from substances produced
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TABLE 3 | IEMs identified by each of the Tier 1 diagnostic tests.
Source Diagnostic
Test
Related IEM
BLOOD: Comprehensive
metabolic
panel
Glucose (low in FAODs and HIHA)
Anion gap (elevated in organic acidemias)
Liver transaminases (elevated in CDGs and
mitochondrial depletion syndromes)
Alkaline phosphatase (low in
hypophosphatasia, elevated in GPI
biosynthesis defects)
Blood gases Organic acidemias (low pH)
Urea cycle disorders (high pH)
Ammonia Urea cycle disorders
Organic acidemias
HIHA
HHH syndrome
Lysinuric protein intolerance
Pyruvate carboxylase deficiency
Creatine
kinase
FAODs
Dystroglycanopathy type-CDG
Uric acid Molybdenum cofactor deficiency (low)
Lactate/pyruvate PDH deficiency
Pyruvate carboxylase deficiency
Biotinidase deficiency
Mitochondrial respiratory chain defects
Lipoic acid synthesis defects
Plasma amino
acids
Urea cycle defects (elevated Glu)
MSUD (elevated branched-chain amino acids)
Tetrahydrobiopterin deficiencies (elevated Phe)
Lactic acidemias (elevated Ala)
Pyruvate carboxylase deficiency (elevated Cit,
Pro & Lys, low Glu)
PNPO deficiency (high Gly and Thr)
PDE (high Gly and Thr)
Non-ketotic hyperglycinemia (elevated Gly)
Hyperprolinemia type 2 (elevated Pro)
Lipoic acid synthesis disorders (elevated Gly)
Serine biosynthesis disorders (low Ser)
Glutamine synthetase deficiency (low Gln)
Asparagine synthetase deficiency (low Asn)
GABA transaminase (elevated GABA, elevated
beta-Ala)
Mitochondrial glutamate transporter deficiency
(elevated Pro)
Molybdenum cofactor deficiency (low Cys, high
Tau)
Isolated sulfite oxidase deficiency (low Cys,
high Tau)
Plasma
acylcarnitines
FAODs
Organic acidemias
Ethylmalonic encephalopathy
Copper and
ceruloplasmin
Menkes disease (low)
Wilson disease (low)
Plasma total
homocysteine
Cobalamin C disease (high)
MTHFR Deficiency (high)
(Continued)
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TABLE 3 | Continued
Source Diagnostic
Test
Related IEM
Molybdenum cofactor deficiency (low)
Isolated sulfite oxidase deficiency (low)
URINE: Urinalysis Organic acidemias (elevated ketones)
MSUD (elevated ketones)
Urine AASA PDE
Molybdenum cofactor deficiency
Isolated sulfite oxidase deficiency
Urine purines
and
pyrimidines
Adenylosuccinate lyase deficiency (high
succinyladenosine)
Molybdenum cofactor deficiency (high xanthine
and hypoxanthine)
Creatine
metabolites
AGAT deficiency (low GAA and creatine)
GAMT deficiency (high GAA, low creatine)
Creatine transporter deficiency (high creatine)
Urine organic
acids
PNPO deficiency (vanillactate)
Organic acidurias
OTC deficiency (orotic acid)
Cobalamin C deficiency (MMA)
Biotinidase deficiency and holocarboxylase
synthetase deficiency (3-hydroxypropionic acid,
3-hydroxyisovaleric acid,
3-methylcrotonylglycine, methylcitrate)
Fumarate hydratase deficiency (fumarate)
SSADH deficiency (4-hydroxybutyric acid)
Ethylmalonic encephalopathy (EMA)
Mitochondrial short-chain enoyl-CoA hydratase
1 deficiency (methacrylylglycine,
3-hydroxyisobutyric acid,
S−2-carboxypropyl-cysteine and
S−2-carboxypropylcysteamine).
AGAT, arginine:glycine amidinotransferase; CDG, congenital disorders of glycosylation;
EMA, ethylmalonic acid; Fatty acid oxidation disorders, FAODs; GAA, guanidinoacetate;
GAMT, guanidinoacetate methyltransferase; HHH, Hyperornithinemia-hyperammonemia-
homocitrullinuria; HIHA, Hyperinsulinism-hyperammonemia syndrome; MSUD, maple
syrup urine disease; MTHFR, methylenetetrahydrofolate reductase; PDE, pyridoxine-
dependent epilepsy; PDH, pyruvate dehydrogenase; PNPO, pyridox(am)ine 5’-phosphate
oxidase; SSADH, succinic semialdehyde dehydrogenase.
in the brain; this means that the more CSF that is drawn, the
higher the values of HVA and 5HIAA will go–in fact, values can
double with every 5ml of CSF drawn (31). The reference ranges
are established by each laboratory using a specific CSF fraction.
Thus, clinicians should adhere to a sampling protocol with
numbered tubes, following the specific instructions provided
by the laboratory performing the test. Gradients also exist
for certain amino acids, with GABA and taurine exhibiting
a rostrocaudal gradient, while alanine and asparagine show a
reverse gradient (32). Additionally, tetrahydrobiopterin (BH4)
is extremely sensitive to oxygen and light, so the tube used to
collect BH4 should contain antioxidants and stored in dark to
protect the sample integrity. Finally, the CSF samples should
be immediately frozen at the bedside. However, if the lumbar
puncture was traumatic, blood cells should be removed by
centrifugation (to avoid metabolite oxidation by products of
hemolyzed RBCs), and only clear CSF should be frozen in
new tubes (31). Although neurotransmitter analysis may still be
possible, the serum component of the blood is not removed by
centrifugation, and thus the CSF amino acid analysis would still
havemajor artifacts in the setting of a traumatic lumbar puncture.
Hence, a repeat lumbar puncture might be needed in this
setting.
Genomics, Metabolomics, and
Multi-Omics Approaches
During the past few years, the field of genomics has seen
the advent of faster and cheaper technologies that have
revolutionized clinical care. In the field of epilepsy in particular, a
recent paper described a diagnostic yield of 14% (49 diagnosed
patients out of 349 patients with drug-resistant pediatric
epilepsy) when 30 genes were sequenced, while expanding
the sequencing panel to 95 genes increased the diagnostic
yield to 20.3% (71/349 patients) (33). It is important that if
any such epilepsy sequencing panel is offered, that all genes
known to be associated with our list of treatable metabolic
epilepsies be included, given the important management
implications.
A recent study described a small cohort of 32 patients
with epileptic encephalopathy who had undergone prior
testing including neurologic and genetics consultations,
metabolic screening, neuroimaging, neurophysiologic studies,
chromosomal microarray, and targeted genetic testing. In this
cohort, the diagnostic yield of whole exome sequencing was 50%
(16/32 patients), and it was the most cost-effective way to reach a
diagnosis, with a cost approximately 10 times less than a standard
diagnostic approach (34). There are, however, limitations to the
use of either a sequencing panel or whole exome sequencing.
As an example, a recent study integrated alternative transcripts
for known neonatal epilepsy genes with RNA-Seq, and found
that in 30% of cases (89 brain-expressed alternative coding
regions in 292 neonatal epilepsy genes) the alternative transcripts
corresponded to a noncoding segment in the canonical transcript
analyzed by standard clinical tests (35). This is important because
in some cases, pathogenic variants were found in these non-
canonical brain transcripts; furthermore, half to two-thirds of
these alternative coding regions are captured by common exon
capture kits, even though these normally fall out of the scope of
analysis. Another limitation of the next-generation sequencing
approach is that in general the turnaround time for results is
longer than for the standard biochemical tests mentioned so
far; thus, the biochemical workup for treatable etiologies of
metabolic epilepsies should not be postponed, and should occur
previously to or concurrently with the genomic workup. Also,
the results can be complimentary, with biochemical findings
confirming or ruling out the functional effect of variants of
unknown significance, while in other cases with negative exome
results, biochemical abnormalities may point to the perturbed
pathway enabling a targeted or manual inspection of candidate
genes for any missed or cryptic variants.
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TABLE 4 | IEMs identified by Tier 2 diagnostic tests.
Diagnostic test Related treatable IEM Related non-treatable IEM
Blood smear Juvenile neuronal ceroid lipofuscinosis, GM1
gangliosidosis, Salla disease, fucosidosis (vacuolated
lymphocytes)
Carbohydrate-deficient
transferrin
Disorders of glycosylation
feat: Intellectual disability, ataxia, inverted nipples, abnormal fat
pads.
Leukocyte CoQ10 Primary CoQ10 deficiency
feat: Encephalomyopathy, nephrotic syndrome, hearing loss,
cerebellar ataxia.
Blood Enzyme Activity:
• Glucocerebrosidase
• Arylsulfatase-A
• Biotinidase
• PPT1/TPP1
Metachromatic leukodystrophy
feat: Dementia, psychosis/(manic-) depression, behavioral
disturbance, spasticity, neuropathy.
Biotinidase deficiency feat: Encephalopathic crisis,
sensorineural hearing loss, eczema, alopecia.
Gaucher disease type 3 feat: Dementia, horizontal supranuclear
gaze palsy. Epilepsy.
Neuronal ceroid lipofucinosis feat: accumulation of
autofluorescent ceroid lipopigments, retinal pathology leading to
blindness, dementia, epilepsy.
Very long chain fatty acids X-linked adrenoleukodystrophy
feat: cognitive deficits, progressive demyelination of CNS, visual
loss, sensorineural deafness, convulsions and dementia.
Peroxisomal biogenesis disorder (Zellweger spectrum)
feat: developmental delay, hypotonia, vision problems, hearing
loss, liver dysfunction, renal cysts, epiphyseal stippling,
demyelination.
Urine oligosaccharides GM2 gangliosidosis (Tay-Sachs disease, Sandhoff disease)
feat: cherry-red spot, hypotonia, hepatosplenomegaly, ataxia,
myoclonus, spastic tetraparesis, decerebration
Sialidosis
feat: Type I: cherry-red spot, myoclonus syndrome (responds
to alcohol), gait abnormalities, epilepsy. Type II: progressive
psychomotor decline, facial dysmorphism, myoclonus, kyphosis
Aspartylglucosiminuria
feat: slowly developing mental decline, beginning with clumsiness,
late speech, hyperkinesia, mild facial dysmorphism, slight
kyphoscoliosis
Urine sialic acid Salla disease
feat: Hypotonia, progressive neurodegeneration, hypomyelination.
Urine sulfocysteine Molybdenum cofactor and isolated sulfite oxidase
deficiencies
feat: epileptic encephalopathy, lens dislocation, hyperekplexia,
multicystic encephalomalacia.
CSF:plasma glucose ratio GLUT1 deficiency
feat: Ataxia, cerebral atrophy, epilepsy, non-epileptic movement
disorder.
CSF lactate/pyruvate GLUT1 deficiency Mitochondrial disorders
CSF amino acids Serine biosynthesis disorders
feat: Epilepsy, neuropathy, cerebral atrophy, microcephaly,
ichthyosis. Severe forms with Neu-Laxova syndrome.
Nonketotic hyperglycinemia feat: apnea, corpus callosum
dysgenesis, epilepsy.
Glutamine synthetase deficiency
feat: epileptic encephalopathy, delayed gyration, necrolytic
erythema
Asparagine synthetase deficiency
feat: epileptic encephalopathy, spastic quadriplegia, microcephaly,
hyperekplexia.
CSF biogenic amines and
BH4
Tetrahydrobiopterin deficiencies
• DHPR deficiency: Developmental delay, epilepsy,
microcephaly, Parkinsonism, cerebral atrophy and basal ganglia
calcifications.
• AR GTPCH deficiency: Developmental delay, epilepsy,
microcephaly, truncal hypotonia, limb hypertonia.
• PTPS deficiency: Developmental delay, epilepsy, microcephaly,
Parkinsonian dystonia, lethargy, autonomic dysfunction.
Tyrosine Hydroxylase deficiency feat: dystonia, postural
tremor, developmental and motor delay, limb rigidity,
hypokinesia, ptosis and oculogyric crisis.
(Continued)
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TABLE 4 | Continued
Diagnostic test Related treatable IEM Related non-treatable IEM
AADC deficiency Developmental delay, hypotonia, autonomic
symptoms, non-epileptic movement disorder, oculogyric crises,
epilepsy.
CSF tetrahydrofolate FOLR1 deficiency feat: psychomotor decline, epilepsy with drop
attacks, progressive movement disorder, hypomyelination.
MTHFR deficiency feat: developmental delay, hypotonia, apnea,
epilepsy, thrombosis, brain atrophy.
DHFR deficiency feat: megaloblastic anemia, seizures.
Serine biosynthesis disorders feat: Microcephaly,
developmental delay, spasticity, seizures, neuropathy, ichthyosis.
FIGURE 1 | Diagnostic algorithm for metabolic epilepsies.
Another diagnostic possibility available in this day and age
is that of metabolomics, which is widely available on a research
basis, but is only offered on a clinical basis by a single laboratory
in the US. In this laboratory, the use of clinical metabolomics
led to the diagnosis of three patients with GABA transaminase
deficiency, siblings with L-2-hydroxyglutaric aciduria, one
patient with aromatic amino acid decarboxylase deficiency,
and one patient with adenylosuccinase deficiency in a single
year (36). In addition to diagnostics, the use of metabolomics
and the combined approach of genomics and metabolomics
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approaches can lead to the identification of novel biomarkers,
and can be used to confirm pathogenicity of variants of unknown
significance (37).
Referral to Metabolic Diseases Specialist
For any patient who shows abnormalities on any of the tier 1
or 2 metabolic tests (even before confirmation of an IEM), the
biochemical physician on-call should be contacted as soon as
possible for further diagnostic testing and management. Other
features that should prompt referral to a metabolic specialist
include
• Progressive symptoms suggestive of neurodegeneration
• Developmental regression or plateauing
• Significant behavioral deterioration from baseline pattern
• Refractory seizures
• Unexplained movement disorder
• MRI/S of the brain showing unexplained abnormalities
• Recurrent/unexplained emesis
• Coarse facial features
• Hepato- and/or splenomegaly
• X-ray evidence of skeletal dysplasia
• Documented episodes of:
– Hypoglycemia
– Significant metabolic acidosis
– Ketonuria (unusual for clinical circumstances).
The full diagnostic algorithm can be found in Figure 1.
CONCLUSION
Based on a literature review, we provide an updated algorithm
for the diagnosis of metabolic epilepsies, taking into account
the description of novel IEMs in recent years up to 2018.
The clinician’s expertise and insights into the patient’s clinical
presentation remain paramount in the diagnostic work-up, as
reflected in our algorithm. In fact, for several IEMs, treatment
should be started even before confirmation of diagnosis. Our
protocol includes tests chosen according to amenability to
treatment of the IEMs potentially identified by the test, diagnostic
yield, availability, and affordability. This algorithm is meant to
provide a structure to the diagnostic workup, but does not claim
to be exhaustive. In fact, the current protocol should be regularly
updated in order to accommodate newly discovered IEMs and
treatments in the future.
To conclude, this protocol has been developed as a
standardized testing procedure to increase diagnostic efficacy
of those IEMs amenable to treatment as well as reduce
costs and diagnostic delay. While this protocol has been
organized based upon literature and clinical observations, it is
ultimately reliant upon the attending clinician’s best judgment to
implement an optimal investigative plan according to established
parameters. In fact, the current protocol should be regularly
updated in order to accommodate newly discovery IEMs, such
as uridine-responsive encephalopathy due to biallelic CAD
mutations and vitamin B6-responsive epileptic encephalopathy
due to biallelic PLPBP mutations (38, 39). Aside from exome
sequencing, entry into the clinical arena of integrated multi-
omics analyses such as metabolomics and transcriptomics will
certainly catalyze such discoveries further (40). Finally, approval
of novel treatments such as gene therapy for metachromatic
leukodystrophy (41, 42) will require regular updates of the
current protocol, and this is favorable news for our patients and
families.
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